Table 2 Results of the systematic literature review regarding median TSW in months
| Â | Sacituzumab Govitecan [41] | Eribulin [40] | Capecitabine [40] | Vinorelbine |
|---|---|---|---|---|
GHS/QoL | 2.80 | 6.2 | 6.0 | -- |
Physical functioning | 5.90 | -- | -- | -- |
Role functioning | 2.10 | -- | -- | -- |
Emotional functioning | 5.90 | -- | -- | -- |
Cognitive functioning | 3.30 | -- | -- | -- |
Social functioning | 3.30 | -- | -- | -- |
Body image | -- | 6.7 | 6.0 | -- |
Future perspective | -- | 6.0 | 4.8 | -- |
Systemic therapy side-effects | -- | 4.9 | 7.2 | -- |
Fatigue | 1.60 | 8.9 | 6.1 | -- |
Nausea/vomiting | 2.10 | 9.9 | 6.5 | -- |
Dyspnea | 6.90 | -- | -- | -- |
Pain | 4.90 | 8.1 | 5.4 | -- |
Diarrhea | 2.00 | 11.6 | 6.6 | -- |
Appetite loss | 3.00 | -- | -- | -- |
Constipation | 3.60 | -- | -- | -- |
Insomnia | 4.10 | -- | -- | -- |